Miguel Ruiz Torres
@ashfromamike.bsky.social
Postdoctoral Researcher at the Lung Cancer Clinical Research Unit at CNIO-H12O
Presenting our PDX platform at the first @sosclc-aecc.bsky.social thanks for the invite!
November 7, 2025 at 12:32 PM
Presenting our PDX platform at the first @sosclc-aecc.bsky.social thanks for the invite!
So excited to share that I've been selected for my first project as a Principal Investigator! Thanks to AECC for this honor!
www.contraelcancer.es/es/area-inve...
www.contraelcancer.es/es/area-inve...
Sinergias AECC 2025
Apoyamos a investigadores en las primeras etapas de su carrera para que puedan desarrollar sus ideas y dirigir una propuesta trabajando de forma colaborativa con jefes de grupo establecidos, formando ...
www.contraelcancer.es
October 16, 2025 at 4:08 PM
So excited to share that I've been selected for my first project as a Principal Investigator! Thanks to AECC for this honor!
www.contraelcancer.es/es/area-inve...
www.contraelcancer.es/es/area-inve...
Presenting poster at #aseicacongress
October 8, 2025 at 10:20 PM
Presenting poster at #aseicacongress
Reposted by Miguel Ruiz Torres
Cx43 Boosts BRAF/MEK Inhibitor Effect via DNA Repair Reduction
In a groundbreaking study published in Nature Communications, a team of researchers, led by Varela-Vázquez and colleagues, has unveiled a critical molecular mechanism by which connexin 43 (Cx43) modulates the effectiveness of BRAF and…
In a groundbreaking study published in Nature Communications, a team of researchers, led by Varela-Vázquez and colleagues, has unveiled a critical molecular mechanism by which connexin 43 (Cx43) modulates the effectiveness of BRAF and…
Cx43 Boosts BRAF/MEK Inhibitor Effect via DNA Repair Reduction
In a groundbreaking study published in Nature Communications, a team of researchers, led by Varela-Vázquez and colleagues, has unveiled a critical molecular mechanism by which connexin 43 (Cx43) modulates the effectiveness of BRAF and MEK inhibitors in cancer therapy. This discovery could have profound implications for the treatment of malignancies harboring BRAF mutations, such as melanoma, by revealing a new layer of vulnerability in cancer cells linked to their DNA repair capabilities.
scienmag.com
July 4, 2025 at 3:57 PM
Cx43 Boosts BRAF/MEK Inhibitor Effect via DNA Repair Reduction
In a groundbreaking study published in Nature Communications, a team of researchers, led by Varela-Vázquez and colleagues, has unveiled a critical molecular mechanism by which connexin 43 (Cx43) modulates the effectiveness of BRAF and…
In a groundbreaking study published in Nature Communications, a team of researchers, led by Varela-Vázquez and colleagues, has unveiled a critical molecular mechanism by which connexin 43 (Cx43) modulates the effectiveness of BRAF and…
Reposted by Miguel Ruiz Torres
Dear new #science #STEM community-
@abireland.bsky.social and I are thrilled to share our latest. The basal cell changes everything for #SCLC #plasticity! Despite prevailing dogma, we now believe the basal cell is the most plausible origin for SCLC because:
@abireland.bsky.social and I are thrilled to share our latest. The basal cell changes everything for #SCLC #plasticity! Despite prevailing dogma, we now believe the basal cell is the most plausible origin for SCLC because:
November 16, 2024 at 1:01 PM
Dear new #science #STEM community-
@abireland.bsky.social and I are thrilled to share our latest. The basal cell changes everything for #SCLC #plasticity! Despite prevailing dogma, we now believe the basal cell is the most plausible origin for SCLC because:
@abireland.bsky.social and I are thrilled to share our latest. The basal cell changes everything for #SCLC #plasticity! Despite prevailing dogma, we now believe the basal cell is the most plausible origin for SCLC because: